These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 29246818)

  • 21. Injectable contraception: emerging evidence on subcutaneous self-administration.
    Lerma K; Goldthwaite LM
    Curr Opin Obstet Gynecol; 2019 Dec; 31(6):464-470. PubMed ID: 31567445
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of two strategies for the administration of injectable depot medroxyprogesterone acetate: among women who returned to a family planning clinic at three- or six-month intervals.
    Ferreira JM; Bottura BF; Gonçalves MP; Monteiro I; Bahamondes L
    Eur J Contracept Reprod Health Care; 2016 Oct; 21(5):408-11. PubMed ID: 27530899
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Costs of administering injectable contraceptives through health workers and self-injection: evidence from Burkina Faso, Uganda, and Senegal.
    Di Giorgio L; Mvundura M; Tumusiime J; Namagembe A; Ba A; Belemsaga-Yugbare D; Morozoff C; Brouwer E; Ndour M; Drake JK
    Contraception; 2018 Nov; 98(5):389-395. PubMed ID: 29859148
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The safety of subcutaneously administered depot medroxyprogesterone acetate (104mg/0.65mL): A systematic review.
    Dragoman MV; Gaffield ME
    Contraception; 2016 Sep; 94(3):202-15. PubMed ID: 26874275
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An implementation project to expand access to self-administered depot medroxyprogesterone acetate (DMPA).
    Katz M; Newmark RL; Aronstam A; O'Grady N; Strome S; Rafie S; Karlin J
    Contraception; 2020 Dec; 102(6):392-395. PubMed ID: 32931811
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Predictors of DMPA-SC continuation among urban Nigerian women: the influence of counseling quality and side effects.
    Liu J; Shen J; Diamond-Smith N
    Contraception; 2018 Nov; 98(5):430-437. PubMed ID: 29733817
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Society of Family Planning committee consensus on self-administration of subcutaneous depot medroxyprogesterone acetate (DMPA-SC).
    Kohn JE; Berlan ED; Tang JH; Beasley A
    Contraception; 2022 Aug; 112():11-13. PubMed ID: 35378085
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Early experience with the contraceptive use of depot medroxyprogesterone acetate in an inner-city clinic population.
    Polaneczky M; Guarnaccia M; Alon J; Wiley J
    Fam Plann Perspect; 1996; 28(4):174-8. PubMed ID: 8853283
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A prospective cohort study of the feasibility and acceptability of depot medroxyprogesterone acetate administered subcutaneously through self-injection.
    Cover J; Namagembe A; Tumusiime J; Lim J; Drake JK; Mbonye AK
    Contraception; 2017 Mar; 95(3):306-311. PubMed ID: 27789309
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Is contraceptive self-injection cost-effective compared to contraceptive injections from facility-based health workers? Evidence from Uganda.
    Di Giorgio L; Mvundura M; Tumusiime J; Morozoff C; Cover J; Drake JK
    Contraception; 2018 Nov; 98(5):396-404. PubMed ID: 30098940
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Preference for Sayana® Press versus intramuscular Depo-Provera among HIV-positive women in Rakai, Uganda: a randomized crossover trial.
    Polis CB; Nakigozi GF; Nakawooya H; Mondo G; Makumbi F; Gray RH;
    Contraception; 2014 May; 89(5):385-95. PubMed ID: 24332432
    [TBL] [Abstract][Full Text] [Related]  

  • 32. An observational study to test the acceptability and feasibility of using medical and nursing students to instruct clients in DMPA-SC self-injection at the community level in Kinshasa.
    Bertrand JT; Bidashimwa D; Makani PB; Hernandez JH; Akilimali P; Binanga A
    Contraception; 2018 Nov; 98(5):411-417. PubMed ID: 30120925
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A Pilot Study of Adolescent and Young Adult Experience with Subcutaneous Depot Medroxyprogesterone Acetate.
    Wernick HJ; Wentzel E; Jackson K; Schmuhl K; Valenti O; Bonny AE; Berlan ED
    J Pediatr Adolesc Gynecol; 2023 Dec; 36(6):549-552. PubMed ID: 37354986
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Introduction of Community-Based Provision of Subcutaneous Depot Medroxyprogesterone Acetate (DMPA-SC) in Benin: Programmatic Results.
    Okegbe T; Affo J; Djihoun F; Zannou A; Hounyo O; Ahounou G; Bangbola KA; Harris N
    Glob Health Sci Pract; 2019 Jun; 7(2):228-239. PubMed ID: 31171559
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Post-abortion depot medroxyprogesterone acetate continuation rates: a randomized trial of cyclic estradiol.
    Goldberg AB; Cardenas LH; Hubbard AE; Darney PD
    Contraception; 2002 Oct; 66(4):215-20. PubMed ID: 12413614
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Update to U.S. Selected Practice Recommendations for Contraceptive Use: Self-Administration of Subcutaneous Depot Medroxyprogesterone Acetate.
    Curtis KM; Nguyen A; Reeves JA; Clark EA; Folger SG; Whiteman MK
    MMWR Morb Mortal Wkly Rep; 2021 May; 70(20):739-743. PubMed ID: 34014910
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Introducing the subcutaneous depot medroxyprogesterone acetate injectable contraceptive via social marketing: lessons learned from Nigeria's private sector.
    Liu J; Schatzkin E; Omoluabi E; Fajemisin M; Onuoha C; Erinfolami T; Ayodeji K; Ogunmola S; Shen J; Diamond-Smith N; Sieverding M
    Contraception; 2018 Nov; 98(5):438-448. PubMed ID: 30071196
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Women's experiences after Planned Parenthood's exclusion from a family planning program in Texas.
    Woo CJ; Alamgir H; Potter JE
    Contraception; 2016 Apr; 93(4):298-302. PubMed ID: 26680757
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Acceptability of Contraceptive Self-Injection with DMPA-SC Among Adolescents in Gulu District, Uganda.
    Cover J; Lim J; Namagembe A; Tumusiime J; Drake JK; Cox CM
    Int Perspect Sex Reprod Health; 2017 Dec; 43(4):153-162. PubMed ID: 29771679
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Depo Provera. Position paper on clinical use, effectiveness and side effects.
    Bigrigg A; Evans M; Gbolade B; Newton J; Pollard L; Szarewski A; Thomas C; Walling M
    Br J Fam Plann; 1999 Jul; 25(2):69-76. PubMed ID: 10454658
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.